ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
Pipe
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
ESG Report
IR
Stock Index
Official Notice
PR
IR LETTER
Press
Library
CAREERS
Recruiting
ENG
Korean
English
Chinese
Best-in-class
anticancer
drug
HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
IR Letter
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t...
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Press Release
PSMC emerges as core of HLB Group i...
PSMC will change its name to HLB innoVation at a shareholder meeting next month to emerge as the HLB Group’s key unit in...
HLB's anticancer drug receives gree...
The combination use of Jiangsu Hengrui Medicine’s camrelizumab and HLB Bio’s rivoceranib has received a novel drug appro...
Report
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...